ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy

Chicago - Circa May 2021: Walgreens Retail Location. Walgreens operates as the second-largest pharmacy store chain in the United States. - Stock Editorial Photography

Walgreens Boots Alliance Inc. (NASDAQ: WBA) is a leading global retail pharmacy and healthcare company. The stock is trading down 60% from its 52-week high and with a stock performance down 58.5% year-to-date (YTD). The market has punished this stock and its (remaining) top competitor, CVS Health Co. (NYSE: CVS), in the retail/wholesale sector. Competition from all fronts, including online pharmacies like Amazon.com Inc. (NASDAQ: AMZN) to department stores with pharmacies and household products like Walmart Inc. (NYSE: WMT) and Target Co. (NYSE: TGT), have eroded Walgreens's market share. Yet, its third quarter of 2024 earnings release is fueling positive sentiment in the stock as the company tries to climb its way back. Here are four reasons to consider buying the stock now.

1) The Turnaround Is Taking Shape as Growth Metrics Improve

Unlike CVS Health, which had a 9% year-over-year (YoY) revenue decline in its recent quarter, Walgreens saw its revenue grow 6% YoY to $37.5 billion, beating consensus estimates by $200 million in its fiscal fourth quarter of 2024. The company earned 39 cents per share, beating consensus estimates by 3 cents. Also, unlike CVS Health, which is also a payor through its Aetna health insurance subsidiary, Walgreens's healthcare segment operates as providers. This has shielded them from the growing medical benefits ratio (MBR) that insurers are seeing cutting into their margins, notably with their Medicare Advantage members.

Walgreens Pharmacy sales rose 9.6% YoY, with strong comparable (comp) pharmacy sales up 11% YoY. However, Retail sales dropped 3.5% YoY as comps fell 1.7% YoY. Its VillageMD revenues rose 7.2% YoY as fee-for-service revenues rose. Its Shields revenue rose 27.8% YoY, driven by growth within existing partnerships. Walgreens exceeded its target of $1 billion in cost savings in fiscal 2024.

Walgreens is also planning to trim costs by shuddering 1,200 underperforming stores over the next three years, starting with 500 in fiscal 2025. This is expected to boost free cash flow and adjusted EPS immediately.

2) Its Assets Are Worth More Than Its Market Capitalization  

Walgreens's 10-K lists its current assets at $18.34 billion, which is twice its current market capitalization (cap) of $9.33 billion. Its property, plant, and equipment, valued at $9.8 billion, exceeds its current market cap. Of course, they still have total short-term and long-term debt combined, totaling $32.67 billion, which is significant. However, the interest rate cut cycle should improve its financing costs.

Approximately 78% of the U.S. population live within five miles of a Walgreens or Duane Reade, which provides convenient proximity for its healthcare services. Walgreens Find Care is a telehealth platform that connects patients and customers with healthcare options from the mobile app. The company operates over 13,000 stores worldwide, including 3,688 retail Boots stores and optician locations in the United Kingdom. Walgreens is still a major shareholder of drug and healthcare products distributor Cencora Inc. (NYSE: COR), formerly AmerisourceBergen, which it still owns 10% of, valued at around $4 billion.

3) Its Valuation Is Historically Cheap, With Prices Not Seen Since 1997

WBA stock is trading at historically cheap levels at just 3.79x forward earnings (forward P/E). Its Price-to-book (P/B) ratio is 0.33. Its price-to-cash flow is 1.37. Its price-to-sales (P/S) is 0.06. Even at $10.79 per share, it's trading at levels not seen since 1998.

WBA is the highest-paying dividend stock in the S&P 500, with a 9.25% annual dividend yield. It's also a potential reality of WBA being removed from the S&P 500 index after being replaced by Amazon in the Dow Jones Industrial Average (DJIA) on Feb. 26, 2024.

While the stock is up 15.4% year-to-date (YTD), it may get a Santa Clause rally and a January Effect rally from end-of-year tax loss selling from long-term shareholders portfolio balancing or just throwing in the towel.

4) WBA Stock Is Forming a Cup and Handle Pattern

A cup pattern is completed when the stock falls from a swing-high cup lip line to a low one, forms a rounding bottom and rallies back to retest the cup lip line. The handle forms when the stock pulls back from the cup lip line, surges back up, and remains above the cup lip line, which becomes a price support level.

Walgreens Boots Alliance WBA stock chart

WBA formed the cup lip line at $11.14 as shares fell to a low of $8.25, forming a rounding bottom that staged a rally back to the $11.14 lip line test. WBA shares are in a pullback, which can form the handle when it reverses and trigger the cup and handle breakout if it can surge through and remain above the $11.14 lip line. The daily anchored VWAP support is rising at $9.52. The daily RSI rose to the 62-band. Fibonacci (Fib) pullback support levels are at $10.72, $10.19, $8.93, and $8.25.

Walgreens Boots Alliance’s average consensus price target is $13.38, and its highest analyst price target sits at $22.00. It has two analysts' Buy ratings, eight Hold, and four Sell ratings. The stock has a 13.3% short interest.

Actionable Options Strategies: Bullish investors can consider using cash-secured puts to buy WBA at the Fib pullback support levels for entry and write covered calls to execute a wheel strategy for income in addition to the 9.27% annual dividend yield.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.